Chemotherapy in Prostate Cancer: Why, When and How?-Interview with Fred Saad

Chemotherapy in Prostate Cancer: Why, When and How? - Presentation Highlights, an Interview with Alicia Morgans and Fred Saad 

Presentation from the 2017 annual LUGPA meeting in Chicago, IL

(Length of interview: 11 min)

In this interview with Alicia Morgans, Fred Saad provides insight into the role of chemotherapy today when treating prostate cancer. There are many drugs now available that are non-chemotherapeutic, easy to administer and with few side effects, however the role of chemotherapy should continue to be on the forefront of treatment. It’s important for physicians to consider not just a single therapy, but multiple agents to ensure greater results for their patients.

View More Exclusive Coverage From LUGPA 2017

Additional Related Content:

Watch:Fred Saad's Lecture at LUGPA 2017: Chemotherapy in Prostate Cancer: Why, When and How?   

Watch: Delay Chemotherapy in Hormone Sensitive Metastatic Prostate Cancer - Michael Cookson

The evolving role of chemotherapy in prostate cancer.

Fred Saad MD FRCS, is full time professor and Chief of Urology and Director of G-U Oncology at the University of Montreal Hospital Centers (CHUM). He holds the U of M Endowed Chair in Prostate Cancer Research and is Director of the molecular oncology research lab in Prostate Cancer. He is the past Chair of the National Cancer Institute of Canada G-U Group and the Canadian Urologic Oncology Group. Dr. Saad has been involved in most of the important clinical trials in advanced prostate cancer over the last 20 years and presently sits on 7 steering committees of international clinical trials. In 2014 he received the lifetime achievement award for research from the CHUM Research Center.

Alicia Morgans, MD